Biocompatibility of PCL-HA Hybrid with Bone Marrow Derived Osteogenetic and Vasculogenetic Cells

摘要

HA is considered to be biocompatible and bioactive due to the similarity of its chemical composition to the mineral phase of bone. The addition of HA to PCL effectively improve the bioactivity of PCL in this study. Results indicated that HA incorporated in PCL significantly increased the viability of osteoblasts and expression of osteoblastic markers (ALP) in a dose-dependent manner. Endothelial progenitor cells, the precursor of endothelial cells, persist in bone marrow stroma normally, and being considered potential seeding cells for vascularization of tissue engineered organs. The capacity of endothelial cells releasing NO, which play an important role in anti-thrombosis and anti-atherogenesis, acted as a criterion of endothelial activity. A low concentration of HA (HA:PCL=1:4) raised NO production in comparison with groups of using higher HA concentrations (HA:PCL=1:1) or the HA-free group, although the endothelial cells viability of all groups were equivalent, which indicated possibly the activity of endothelial cells is independent of the concentration of HA involved in PCL.